Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy

[11] Boon MC(2005)Evolving chemotherapy for advanced gastric cancer Oncologist 10 49-58

[12] Hermans J(2007)Adjuvant and neoadjuvant approaches in gastric cancer Cancer J 13 168-174

[13] Bonenkamp JJ(2000)The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil Pharmacology 61 199-203

[14] Earle CC(2006)Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway Gastric Cancer 9 145-155

[15] Maroun JA(2004)Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine World J Gastroenterol 10 172-176

[16] Mari E(2002)Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer Anticancer Res 22 2805-2809

[17] Floriani I(1996)Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival J Clin Oncol 14 176-182

[18] Tinassi A(1995)Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res 55 1407-1412

[19] Panzini I(1992)Quantitation of thymidylate synthase, dihydroreductase and DT-diaphorose gene expression in human tumors using the polymerase chain reaction Cancer Res 52 108-116

[20] Gianni L(1995)Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial Eur J Cancer 31A 1306-1310

[11] Boon MC(2005)Evolving chemotherapy for advanced gastric cancer Oncologist 10 49-58

[12] Hermans J(2007)Adjuvant and neoadjuvant approaches in gastric cancer Cancer J 13 168-174

[13] Bonenkamp JJ(2000)The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil Pharmacology 61 199-203

[14] Earle CC(2006)Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway Gastric Cancer 9 145-155

[15] Maroun JA(2004)Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine World J Gastroenterol 10 172-176

[16] Mari E(2002)Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer Anticancer Res 22 2805-2809

[17] Floriani I(1996)Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival J Clin Oncol 14 176-182

[18] Tinassi A(1995)Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res 55 1407-1412

[19] Panzini I(1992)Quantitation of thymidylate synthase, dihydroreductase and DT-diaphorose gene expression in human tumors using the polymerase chain reaction Cancer Res 52 108-116

[20] Gianni L(1995)Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial Eur J Cancer 31A 1306-1310